基因组分析在髓系肿瘤和急性白血病临床决策中的应用
该文阐述髓系肿瘤和急性白血病由体细胞基因突变驱动的克隆扩增,传统细胞遗传学仍是基因组检测的基石,而靶向基因 panel、全外显子测序、全基因组测序和 RNA 测序等新技术提高了突变检出能力。文章旨在帮助医生和检验人员实施基因组检测以用于诊断、风险分层和临床决策,并说明基因组分析实现个性化医疗的潜力。
要点
- 髓系肿瘤和急性白血病的基因组特征对准确诊断、风险评估和治疗决策日益重要。
- 传统细胞遗传学仍是基因组检测的基石,高通量测序技术提高了体细胞突变检出能力。
- 全基因组测序可能替代传统细胞遗传学和测序方法,提供快速、全面的基因组分析。
核心结论
- 基因组分析有助于髓系肿瘤和急性白血病患者的诊断、风险分层和临床决策,并展现了个性化医疗的潜力。
研究设计与样本
- 本文为综述,旨在帮助医生和检验人员实施基因组检测用于诊断、风险分层和临床决策。
主要发现
- 髓系肿瘤和急性白血病源于体细胞基因突变驱动的造血细胞克隆扩增。
- 传统细胞遗传学在过去数十年中是基因组检测的主要方法,至今仍适用。
- 靶向基因 panel、全外显子测序、全基因组测序和全转录组测序或 RNA 测序等新技术提高了体细胞突变检出能力。
- 在髓系肿瘤患者中,全基因组测序可能替代传统细胞遗传学和测序方法,提供快速、准确的全面基因组分析。
- DNA 测序不仅用于检测体细胞获得性基因突变,也用于识别与遗传性血液肿瘤易感性相关的胚系基因突变。
关键数值与推荐
- 2022 年国际共识分类(International Consensus Classification)在髓系肿瘤和急性白血病中大量使用基因组数据。
临床怎么用
- 文章旨在帮助医生和检验人员实施基因组检测以用于诊断、风险分层和临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today. However, more recent advances in sequencing technology have increased our ability to detect somatic mutations through the use of targeted gene panels, whole-exome sequencing, whole-genome sequencing, and whole-transcriptome sequencing or RNA sequencing. In patients with myeloid neoplasms, whole-genome sequencing represents a potential replacement for both conventional cytogenetic and sequencing approaches, providing rapid and accurate comprehensive genomic profiling. DNA sequencing methods are used not only for detecting somatically acquired gene mutations but also for identifying germline gene mutations associated with inherited predisposition to hematologic neoplasms. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias makes extensive use of genomic data. The aim of this report is to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with hematologic neoplasms.
引用
- Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022. PMID: 36130297. doi:10.1182/blood.2022015853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。